Paliperidone Teva Italia (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidone Teva Italia, is an atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It treats schizophrenia and schizoaffective disorder in adult patients. GNH USA supplies Paliperidone Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone palmitate is an atypical antipsychotic indicated for the treatment of schizophrenia spectrum disorders. - Schizophrenia: Reduces risk of relapse and controls psychotic symptoms such as delusions and hallucinations. - Schizoaffective disorder: Stabilises mood and psychotic features, helping maintain functional improvement. - Maintenance therapy after acute stabilization: Provides sustained symptom control with monthly dosing, reducing the need for daily oral medication.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain or erythema - Headache - Fatigue - Restlessness (akathisia) - Nausea - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia or new‑onset diabetes - Seizures - Elevated prolactin with menstrual disturbances or galactorrhoea

Before initiating therapy with Paliperidone palmitate, clinicians should assess individual risk factors and monitor patients regularly. - Cardiovascular assessment: Evaluate for history of arrhythmias, QT prolongation, or uncontrolled hypertension. - Metabolic monitoring: Check fasting glucose and lipid profile at baseline and periodically. - Movement disorders: Observe for early signs of extrapyramidal symptoms or tardive dyskinesia. - Pregnancy and lactation: Use only if the potential benefit outweighs potential risks to the fetus or infant. - Drug‑interaction review: Verify concomitant medications for CYP‑related or QT‑prolonging agents. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone exposure. - QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce paliperidone levels. - Antihypertensive drugs: may enhance orthostatic hypotension. - CNS depressants (e.g., benzodiazepines, opioids): may increase sedation. - Anticholinergic agents: may mask extrapyramidal symptoms. - Lithium: combined use may increase risk of neurotoxicity.